Biotech Values

[rkrw]

<<NO GENERIC MAKER HAS EVER ACTUALLY PAID DAMAGES FOR LAUNCHING EARLY [emphasis added].>>

I think this statement may be a little misleading because I'm not sure there's much if any precedent wrt launching early.

Generic oxycontin also released by teva but after a lower court ruled in teva's favor, final decision still pending appeal.


<<may not be taking as large a risk as some investors believe.>>

Obviously alo/teva's patent counsel would be est their odds of winning. I imagine they must have been told something north of 95%.

Certainly an interesting development.